search button
Open Access

Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)

  • Authors:
    • Silvia Falcon
    • Luis Riva
    • Christina Flores
    • Delphis Vera
    • Joseph A. Pinto
    • Henry L. Gomez

  • View Affiliations

  • Published online on: January 25, 2022     https://doi.org/10.3892/mco.2022.2503
  • Article Number: 70

  • Copyright: © Falcon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)‑positive breast cancer. The comparison of outcomes between nonrandomized groups of patients who received similar treatments in routine practice remains difficult. The present study aimed to evaluate the pathological complete response (pCR) rates achieved with pertuzumab among patients in routine clinical care in Peru using real‑world data. The definition of pCR used was the absence of residual invasive cancer from the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. A total of 44 patients with non‑metastatic HER2‑positive breast cancer (stages II and III) treated with pertuzumab in the neoadjuvant setting and who underwent surgery at three private clinics in Lima (Peru) were retrospectively evaluated. The pCR was the efficacy endpoint and it was determined and compared with the results from other clinical trials. Furthermore, safety data were described. The median age was 44 years (interquartile range, 39.5‑50.5 years) and 65.9% of patients were premenopausal. Regarding the clinical stage, 56.8% were IIA/IIB and 36.4% were IIIA/IIIB/IIIC. All treatment schemes included concurrent trastuzumab. The patients' treatment comprised neoadjuvant therapy of docetaxel/trastuzumab/pertuzumab (THP) with a median of 4 cycles in 30 patients (68.2%) or docetaxel/trastuzumab/pertuzumab/carboplatin (THPCarb) with a median of 6 cycles in 14 patients (31.8%). In total, 70.5% of patients experienced pCR; among hormone receptor‑negative cases, 75.0% achieved pCR and in tumors expressing hormone receptors, the rate of pCR was 66.7%. Of those patients subjected to neoadjuvant treatment with THP, 66.7% (20/30) achieved pCR, whereas 78.6% (11/14) of patients who received THPCarb had a pCR. The incidence of drug‑related adverse events was 59.1% and in none of the patients, administration was discontinued due to toxicity. The present results of Peruvian patients with HER2 breast cancer treated according to clinical routine demonstrated that dual blockade of HER2 with trastuzumab and pertuzumab in the neoadjuvant setting achieved high rates of pCR even in hormone receptor‑positive patients. These results are consistent with those of randomized controlled trials, with a good safety profile.
View References

Related Articles

Journal Cover

March-2022
Volume 16 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Falcon S, Riva L, Flores C, Vera D, Pinto JA and Gomez HL: Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer). Mol Clin Oncol 16: 70, 2022
APA
Falcon, S., Riva, L., Flores, C., Vera, D., Pinto, J.A., & Gomez, H.L. (2022). Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer). Molecular and Clinical Oncology, 16, 70. https://doi.org/10.3892/mco.2022.2503
MLA
Falcon, S., Riva, L., Flores, C., Vera, D., Pinto, J. A., Gomez, H. L."Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)". Molecular and Clinical Oncology 16.3 (2022): 70.
Chicago
Falcon, S., Riva, L., Flores, C., Vera, D., Pinto, J. A., Gomez, H. L."Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)". Molecular and Clinical Oncology 16, no. 3 (2022): 70. https://doi.org/10.3892/mco.2022.2503